Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health

Autor: Jérôme Wittwer, Christophe Adam, Véronique Raimond, Emmanuelle Kaltenbach, Catherine Le Galès, Sébastien Lazzarotto, Lionel Perrier

Publikováno v: Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2021, ⟨10.1016/j.bulcan.2021.09.001⟩
Bulletin du Cancer, 2021, ⟨10.1016/j.bulcan.2021.09.001⟩

Summary Since 2013, the process of pricing of innovative drugs by the French National Health Insurance has considered both cost-effectiveness and budget impact. CAR-T cell therapies were first subject to economic evaluation from 2019 in France. We ai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49227ff7542306c836856507f29cb838
https://halshs.archives-ouvertes.fr/halshs-03428067

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Autor: Véronique Raimond, Valérie Clément

Publikováno v: Value in Health. 22:220-224

Objective This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework. Study Design Taking the example of new direct-acting antivirals against he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bb59f6e86609363a0806c4371a8cfb
https://doi.org/10.1016/j.jval.2018.08.009

L’évaluation économique des produits de santé innovants : quelle interprétation pour quel usage ?

Autor: Clémence Thébaut, Catherine Rumeau-Pichon, Fabienne Midy, Véronique Raimond

Publikováno v: Revue française des affaires sociales. :263-281

La loi de financement de la securite sociale (LFSS) pour 2012 a introduit le critere d’efficience dans la determination du prix des produits de sante innovants. La mise en œuvre de cette disposition par la Haute Autorite de sante (HAS) et le Comit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c324c0ef1e11b273dbdf9a3562200cb
https://doi.org/10.3917/rfas.163.0263

Early Access Schemes and Pricing Strategies: A Case Study on Temporary Authorization for Use in France from 1994 to 2016

Autor: Xiaoyan Lu, Setti Rais Ali, Pascal Paubel, Albane Degrassat-Théas, Laurie Rachet Jacquet, Véronique Raimond, Lise Rochaix

Publikováno v: Revue française des affaires sociales
Revue française des affaires sociales, La documentation française, 2018, 2018/3, pp.69-89

International audience; Early access schemes for pharmaceuticals have been increasingly implemented worldwide with the objective of satisfying unmet medical needs or facilitating market access for certain innovative drugs. It allows for pharmaceutica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58f807ffedcc5541ad45503130b7c93b
https://halshs.archives-ouvertes.fr/halshs-02096440

Drug price regulation

Autor: Jean-Michel Josselin, Véronique Raimond, Laurie Rachet Jacquet, Lise Rochaix

Publikováno v: Encyclopedia of Law and Economics
Alain Marciano, Giovanni Battista Ramello. Encyclopedia of Law and Economics, Springer Science+Business Media LLC 2017, pp.1-8, 2017, 978-1-4614-7883-6. ⟨10.1007/978-1-4614-7883-6_714-1⟩
Encyclopedia of Law and Economics ISBN: 9781461478836

International audience; Drug prices are regulated in a legal framework that organizes the negotiation between pharmaceutical firms and a third-party payer responsible for healthcare reimbursement. This regulation aims at compensating for market failu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74161c5f75e61b2cec0c447ba19db62e
https://shs.hal.science/halshs-01615092